FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma

• Published in: Respirology (Carlton, Vic.) Vol. 18; no. 4; pp. 734 - 735
• Main Authors: Putora, Paul M., Früh, Martin, Müller, Joachim
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.05.2013
• Subjects: Adenocarcinoma - genetics; Adenocarcinoma - metabolism; Adenocarcinoma - pathology; Case-Control Studies; Cell Proliferation; epidermal growth factor receptor; Fluorodeoxyglucose F18 - metabolism; genetic association; Genotype; Humans; imaging; lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Mutation - genetics; Positron-Emission Tomography - methods; Predictive Value of Tests; primary tumour standardized uptake; Receptor, Epidermal Growth Factor - genetics; Survival Rate
• ISSN: 1323-7799; 1440-1843; 1440-1843
• DOI: 10.1111/resp.12083

Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value (SUVmax) and epidermal growth factor receptor (EGFR) mutation status in lung cancer. We analysed positron emission tomography with fluorodeoxyglucose SUVmax in 14 patients with EGFR mutations, and a control group of 14 subjects with wild‐type EGFR adenocarcinomas. The mean SUV value was 10.7 for EGFR‐mutated adenocarcinomas and 9.9 for wild‐type tumours. There was no correlation between SUV values and EGFR mutation status. Omitting EGFR testing in lung cancers with low SUVmax is not appropriate.